Active immunisation against diphtheria, tetanus and pertussis, Booster immunisation against diphtheria, tetanus and pertussis, Prophylaxis of tetanus in wound management.
How it works
Protection against disease attributable to C tetani is due to the development of neutralizing antibodies to tetanus toxin. A serum tetanus antitoxin level of at least 0.01 IU/mL, measured by neutralization assay, is considered the minimum protective level. A level ? 0.1 to 0.2 IU/mL has been considered as protective. Protection against disease attributable to C diphtheriae is due to the development of neutralizing antibodies to diphtheria toxin. A serum antitoxin level of 0.01 IU/mL is the lowest level giving some degree of protection. Antitoxin levels of at least 0.1 IU/mL are generally regarded as protective. Levels of 1.0 IU/mL have been associated with long term protection. The mechanism of protection from B pertussis disease is not well understood. However, the pertussis components in vaccine have been shown to prevent pertussis in infants in clinical trials.
Common side effects
Pain, Abdominal pain, Diarrhoea, Fever, Headache, Injection site redness, Injection site swelling, Fatigue, Nausea